Clinical Trials

Date: 2022-03-23

Type of information: Presentation of results at a congress

phase: preclinical

Announcement: presentation of results at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation

Company: Vectivbio (Switzerland)

Product: apraglutide

Action mechanism: GLP2 antagonist

Disease: acute graft-versus-host disease (aGVHD)

Therapeutic area: Transplantation

Country:

Trial details:

Latest news:

• On March 23, 2022, VectivBio, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced new preclinical data supporting the potential of apraglutide, a next-generation, long-acting GLP-2 analog, as a novel treatment of steroid-refractory GI aGVHD following allogeneic hemopoietic stem cell transplant (HSCT). The data were presented across four posters at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), taking place virtually March 19-23, 2022.
• The GI tract is one of the key target organ systems damaged by the chemotherapy regimen used in HSCT conditioning and the development of aGVHD, contributing to high morbidity and mortality among HSCT patients. Acute GvHD treatment today is based on immunosuppressive approaches which do not directly target impacted organ systems. GLP-2 targets the GI tract, promoting intestinal healing and regeneration through intestinal epithelial repair, restoration of intestinal barrier function, and maintenance of a healthy microbiome.
• Details of the e-poster presentations are as follows: Title: Apraglutide Decreases Severity of Intestinal Damage from Gastrointestinal (GI) Acute Graft Versus Host Disease (GvHD) Following Allogeneic Transplantation Without Impacting Engraftment Poster Number: #P198 Treatment with apraglutide prior to and following allogeneic transplantation in immunodeficient mice was observed to have a protective effect against the GI damage from conditioning chemotherapy. Notably, apraglutide did not appear to affect engraftment rate, and was observed to reduce GI damage and improve mortality rates in allogeneic-transplant-induced GvHD. Title: Apraglutide Treatment Reduces Chemotherapy-Induced Gastrointestinal (GI) Damage in Mice and Preserves Cellular Integrity During Chemotherapy - Poster Number: #P199 Data showed that apraglutide protected GI epithelium structure from chemotherapy-induced injury, prevented severe body weight loss, and improved survival rates in mice undergoing chemotherapy. Additionally, apraglutide maintained plasma citrulline levels, a marker of intestinal mass, comparable to that in mice that did not undergo chemotherapy. The effects of apraglutide were optimal when it was administered as pre-treatment before chemotherapy. Title: Treatment with Apraglutide Preserves the Global Homeostatic Environment of Intestinal Microbiota During Chemotherapy in Mice - Poster Number: #P200 In mouse models of aGVHD, the co-administration of apraglutide with conditioning chemotherapy avoided damage to the gut common from chemotherapy alone. Results showed the preservation of intestinal microbiome homeostasis, and improved outcomes including reduced body weight loss and increased survival rates. Title: Apraglutide Does Not Impact Anti-tumor and Immunosuppressive Efficacy of Conditioning Chemotherapy in Mice - Poster Number: #P201 The administration of apraglutide as a pre- and concomitant treatment in mouse models of aGVHD did not impair the anti-tumor and immunosuppressive effects of chemotherapy. The pharmacologic effects of apraglutide were observed to be specific to the intestine.

Is general: Yes